PROK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
ProKidney Corp (PROK) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While the company has potential in the biopharmaceutical space and a positive analyst rating, the financial performance is weak, insider selling is significant, and there are no strong technical or proprietary trading signals to support an immediate buy decision.
The MACD is positive but contracting, RSI is neutral at 65.363, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level of 2.112, with resistance at 2.261 and support at 1.963.
Analyst Joseph Pantginis from H.C. Wainwright initiated coverage with a Buy rating and a $12 price target, citing the potential of rilparencel to redefine the therapeutic landscape for chronic kidney disease.
Insider selling has increased by 503.05% over the last month, indicating a lack of confidence from company insiders. Additionally, there is no recent news or significant hedge fund activity to support a bullish sentiment.
In Q3 2025, revenue remained flat at $217,000 YoY, while net income dropped by -8.05% YoY to -$16,469,000. EPS declined by -14.29% YoY to -0.12, reflecting ongoing financial struggles.
H.C. Wainwright initiated coverage with a Buy rating and a $12 price target, highlighting the company's innovative approach in addressing chronic kidney disease.
